Sapience Therapeutics, a leading biotechnology company, recently shared promising clinical and biomarker data from its ST101 Phase 2 study in glioblastoma (GBM) at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. The data revealed durable responses in three cohorts of patients with recurrent and newly diagnosed GBM, supporting the continued development of ST101 as a potential backbone treatment in combination with standard-of-care and immune-oncology agents.
Dr. Fabio M. Iwamoto, from New York-Presbyterian/Columbia University Irving Medical Center, highlighted the encouraging clinical activity of ST101 in GBM patients, showing durable responses, improved survival rates, and positive effects on the tumor microenvironment. These findings pave the way for further exploration of ST101 in combination studies in Phase 2b.
Dr. Both Vainstein-Haras, Sapience’s Chief Medical Officer, emphasized ST101’s impressive clinical results and safety profile, further solidifying C/EBPβ as a promising target for GBM treatment. The biomarker data presented demonstrated the impact of ST101 on the tumor microenvironment, providing a strong rationale for investigating ST101 in combination with immune-oncology agents like checkpoint inhibitors.
Key highlights from the oral presentation included positive outcome data from multiple cohorts of GBM patients, showcasing durable responses and survival benefits with ST101 treatment. Biomarker data from the study cohorts further supported ST101’s potential by demonstrating its ability to penetrate tumor tissue, engage with the target C/EBPβ, and modulate the tumor immune microenvironment for anti-tumor activity.
ST101, a first-in-class antagonist of C/EBPβ, is currently being evaluated in ongoing Phase 1-2 clinical trials for newly diagnosed and recurrent GBM. The Fast Track designation for recurrent GBM and orphan designations for glioma from regulatory agencies underscore the significance of ST101’s development in the field of oncology.
Sapience Therapeutics is committed to advancing its pipeline of therapeutic candidates, including ST316 and ST101, to address the oncogenic and immune dysregulation mechanisms in cancer. Through innovative peptide-based technologies like SPEARs™ and SPARCs™, Sapience aims to target traditionally undruggable transcription factors and deliver payloads to cancer cells effectively.
For more information on Sapience Therapeutics and its groundbreaking research, visit http://www.sapiencetherapeutics.com. Stay connected with us on LinkedIn for the latest updates and insights.
Contact:
Amy Conrad
Juniper Point
(858) 366-3243
amy.conrad@juniperpoint.com
Source: Sapience Therapeutics, Inc.
Source link
